Duloxetine for the treatment of major depressive disorder
Affiliations
- PMID: 12858150
Item in Clipboard
Duloxetine for the treatment of major depressive disorder
Psychopharmacol Bull.
2002 Autumn.
Abstract
>55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.
Similar articles
-
Duloxetine: a review of its use in the treatment of major depressive disorder.CNS Drugs. 2007;21(7):581-609. doi: 10.2165/00023210-200721070-00004. CNS Drugs. 2007. PMID: 17579500 Review.
-
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.J Psychiatr Res. 2006 Jun;40(4):337-48. doi: 10.1016/j.jpsychires.2005.08.010. Epub 2005 Nov 4. J Psychiatr Res. 2006. PMID: 16271726
-
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.Curr Med Res Opin. 2005 Mar;21(3):345-56. doi: 10.1185/030079905X30680. Curr Med Res Opin. 2005. PMID: 15811202 Review.
-
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.J Psychiatr Res. 2005 Jan;39(1):43-53. doi: 10.1016/j.jpsychires.2004.04.011. J Psychiatr Res. 2005. PMID: 15504423 Clinical Trial.
-
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.J Clin Psychiatry. 2002 Apr;63(4):308-15. doi: 10.4088/jcp.v63n0407. J Clin Psychiatry. 2002. PMID: 12000204 Clinical Trial.
Cited by
-
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.Adv Neurobiol. 2021;26:317-347. doi: 10.1007/978-3-030-77375-5_13. Adv Neurobiol. 2021. PMID: 34888840 Free PMC article.
-
A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder.Front Psychiatry. 2021 Jun 17;12:689143. doi: 10.3389/fpsyt.2021.689143. eCollection 2021. Front Psychiatry. 2021. PMID: 34220591 Free PMC article.
-
Neuropharmacological Effects of Mesaconitine: Evidence from Molecular and Cellular Basis of Neural Circuit.Neural Plast. 2020 Aug 21;2020:8814531. doi: 10.1155/2020/8814531. eCollection 2020. Neural Plast. 2020. PMID: 32904549 Free PMC article. Review.
-
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: Study protocol for a randomized, parallel-group, non-inferiority trial.Neuropsychopharmacol Rep. 2019 Dec;39(4):262-272. doi: 10.1002/npr2.12078. Epub 2019 Sep 18. Neuropsychopharmacol Rep. 2019. PMID: 31531962 Free PMC article.
-
Molecular mechanism of noradrenaline during the stress-induced major depressive disorder.Neural Regen Res. 2018 Jul;13(7):1159-1169. doi: 10.4103/1673-5374.235019. Neural Regen Res. 2018. PMID: 30028316 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical